CVRx posted Q3 revenue of $13.8 million, including $13.0 million from the U.S., underscoring its domestic concentration. Active U.S. implanting centers rose to

CVRx posted Q3 revenue of $13.8 million, including $13.0 million from the U.S., underscoring its domestic concentration. Active U.S. implanting centers rose to 262 from 250, as the company outlined a 2026 outlook and recent Barostim milestones.